Evidence map›Paper›PMID 35165278›Full record

ArticleNature communications2022

Rhodium hydride enabled enantioselective intermolecular C-H silylation to access acyclic stereogenic Si-H.

Kun An, Wenpeng Ma, Li-Chuan Liu, Tao He, Guiyu Guan, Qing-Wei Zhang, Wei He

Abstract read
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kun An *MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology and School of Pharmaceutical Sciences, Tsinghua University, Beijing, PR China.
Wenpeng Ma *MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology and School of Pharmaceutical Sciences, Tsinghua University, Beijing, PR China.
Li-Chuan LiuMOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology and School of Pharmaceutical Sciences, Tsinghua University, Beijing, PR China.
Tao HeMOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology and School of Pharmaceutical Sciences, Tsinghua University, Beijing, PR China.
Guiyu GuanMOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology and School of Pharmaceutical Sciences, Tsinghua University, Beijing, PR China.
Qing-Wei ZhangDepartment of Chemistry, University of Science and Technology of China, Hefei, PR China. qingweiz@ustc.edu.cn.ORCID http://orcid.org/0000-0002-8577-6304
Wei HeMOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology and School of Pharmaceutical Sciences, Tsinghua University, Beijing, PR China. whe@mail.tsinghua.edu.cn.ORCID http://orcid.org/0000-0001-8167-9155

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tremendous success of stereogenic carbon compounds has never ceased to inspire researchers to explore the potentials of stereogenic silicon compounds. Intermolecular C-H silylation thus represents the most versatile and straightforward strategy to construct C-Si bonds, however, its enantioselective variant has been scarcely reported to date. Herein we report a protocol that allows for the enantioselective intermolecular C-H bond silylation, leading to the construction of a wide array of acyclic stereogenic Si-H compounds under simple and mild reaction conditions. Key to the success is (1) a substrate design that prevents the self-reaction of prochiral silane and (2) the employment of a more reactive rhodium hydride ([Rh]-H) catalyst as opposed to the commonly used rhodium chloride ([Rh]-Cl) catalyst. This work unveils opportunities in converting simple arenes into value-added stereogenic silicon compounds.

Identifiers

PMID35165278
PMCPMC8844420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.